¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Receptor Activator of Nuclear Factor-kappa B"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • beta-adrenergic receptor kinase
    º£Å¸¾Æµå·¹³¯¸°¼ö¿ëüÀλêÈ­È¿¼Ò
  • cold receptor
    ³Ã°¢¼ö¿ë±â
  • complement receptor
    º¸Ã¼¼ö¿ëü
  • corpuscular receptor
    ¼Òü¼ö¿ëü
  • cell surface receptor
    ¼¼Æ÷Ç¥¸é¼ö¿ëü
  • cholinergic receptor
    Äݸ°¼ö¿ëü
  • distance receptor
    ¿ø°Ý¼ö¿ë±â
  • dominant receptor
    ¿ì¼º¼ö¿ëü
  • early receptor potential
    Á¶±â¼ö¿ëüÀüÀ§, Á¶±â½Ã°¢¼¼Æ÷ÀüÀ§
  • estrogen receptor
    ¿¡½ºÆ®·Î°Õ¼ö¿ëü
  • free receptor
    À¯¸®¼ö¿ëü
  • gustatory receptor
    ¹Ì°¢¼ö¿ë±â
  • H1 receptor
    H1¼ö¿ëü
  • H2 receptor
    H2¼ö¿ëü
  • heat receptor
    ¿­¼ö¿ë±â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • receptor autoradiography
    ¼ö¿ëüÀÚ°¡¹æ»ç¼±¼ú
  • beta-adrenergic receptor kinase
    º£Å¸¾Æµå·¹³¯¸°¼º¼ö¿ëüÀλêÈ­È¿¼Ò
  • receptor binding
    ¼ö¿ëü°áÇÕ
  • receptor blocker
    ¼ö¿ëüÂ÷´ÜÁ¦
  • cell surface receptor
    ¼¼Æ÷Ç¥¸é¼ö¿ëü
  • cholinergic receptor
    Äݸ°¼ö¿ëü
  • cold receptor
    ³Ã°¢¼ö¿ëü
  • complement receptor
    µµ¿òü¼ö¿ëü, º¸Ã¼¼ö¿ëü
  • corpuscular receptor
    ¼Òü¼ö¿ëü
  • receptor cell
    ¼ö¿ëü¼¼Æ÷
  • distance receptor
    (¢¡teleceptor) ¿ø°Ý¼ö¿ëü
  • dominant receptor
    ¿ì¼º¼ö¿ëü
  • early receptor potential
    Á¶±â½Ã°¢¼¼Æ÷ÀüÀ§
  • electromagnetic receptor
    ÀüÀÚ±â¼ö¿ëü
  • receptor destroying enzyme
    ¼ö¿ëüÆÄ±«È¿¼Ò
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • homing receptor
    ±Í¼Ò¼ö¿ëü
  • immunoglobulin receptor
    ¸é¿ª±Û·ÎºÒ¸° ¼ö¿ëü
  • insulin receptor
    Àν¶¸°¼ö¿ëü(áôé»ô÷).
  • insulin receptor
    Àν¶¸°¼ö¿ëü.
  • platelet receptor
    Ç÷¼ÒÆÇ¼ö¿ëü
  • postsynaptic receptor
    ¿¬Á¢Èļö¿ëü
  • prejunctional neuromuscular receptor
    ½Å°æ±ÙÁ¢ÇÕÀü¼ö¿ëü
  • pressor receptor
    ¾Ð·Â¼ö¿ëü(äâæ³áôé»ô÷).
  • pressor receptor reflex
    ¾Ð·Â¼ö¿ëü¹Ý»ç(äâæ³áôé»ô÷ÚãÞÒ).
  • pressure receptor
    ¾Ð¼ö¿ë±â, ¾Ð·Â¼ö¿ëü(¡­áôé»ô÷).
  • progesterone receptor
    ÇÁ·Î°Ô½ºÅ×·Ð(ÇÁ·ÎÁ¦½ºÅ×·Ð)¼ö¿ëü(¡­â¥é»ô÷)
  • receptor
    ¼ö¿ë±â
  • receptor amblyopia
    ¼ö¿ë±â¾à½Ã
  • receptor assay
    ¼ö¿ëÃ¼ÃøÁ¤
  • receptor autoradiography
    ¼ö¿ëü ÀÚ±â¹æ»ç¼±ÃÔ¿µ¼ú
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • nuclear energy
    ÇÙ(ú·)¿¡³ÊÁö.
  • nuclear envelope
    ÇÙ¸·(ú·Ø¯).
  • nuclear fast red
    ÇÙ³»¼º Àû»ö¼Ò(ú·Ò±àõîåßä áÈ).
  • nuclear fission
    Çٺп­(ú·ÝÂæñ).
  • nuclear icterus
    ÇÙȲ´Þ(ú·üÜÓ¸).
  • nuclear inclusion
    ÇÙ³» ºÀÀÔü
  • nuclear inclusion
    ÇÙ³»ºÀÀÔü
  • nuclear induction
    ÇÙ À¯µµ
  • nuclear isomer
    ÇÙÀ̼ºÃ¼
  • nuclear isomer
    ÇÙÀ̼ºÃ¼(ú·ì¶àõô÷).
  • nuclear isomerism
    ÇÙÀ̼º(ú·ì¶àõ).
  • nuclear jaundice
    ÇÙȲ´Þ(ú·üÜÓ¸).
  • nuclear magnetic resonance
    ¹æ»ç (ÇÙÀÇ)ÇÙÀÚ±â°ø¸í.
  • nuclear magnetic resonance (NMR)
    ÇÙÀÚ±â°ø¸í
  • nuclear medicine
    ÇÙÀÇÇÐ(ú·ì¢ùÊ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • receptor destroying enzyme
    ¼ö¿ëü ÆÄ±«È¿¼Ò(áôé»ô÷÷òÎÕý£áÈ)
  • receptor down regulation
    ¼ö¿ëü ÇÏÇâ Á¶Àý(áôé»ô÷ù»ú¾ðàï½)
  • receptor element
    ¼ö¿ëü Á¶Àý ¿ä¼Ò(áôé»ô÷ðàï½é©áÈ)
  • receptor gradient
    ¼ö¿ëü ±¸¹è(áôé»ô÷ÎþÛÕ)
  • receptor internalization
    ¼ö¿ëü ³»ÀÔ(áôé»ô÷Ò®ìý)
  • receptor-mediated endocytosis
    ¼ö¿ëü¸Å°³ ¼¼Æ÷³» ÀÌÀÔ(áôé»ô÷ØÚË¿á¬øàÒ®ì¹ìý)
  • ribosome receptor
    ¶óÀ̺¸¼Ø ¼ö¿ëü(áôé»ô÷)
  • spare receptor
    ¿¹ºñ(çãÝá) ¼ö¿ëü (â¥é»ô÷)
  • SRP receptor
    SRP ¼ö¿ëü(áôé»ô÷)
  • steroid receptor
    ½ºÅ×·ÎÀÌµå ¼ö¿ëü (áôé»ô÷)
  • virus receptor
    ¹ÙÀÌ·¯½º ¼ö¿ëü (â¥é»ô÷)
  • volume receptor
    ¿ëÀû ¼ö¿ë±â(é»îÝáôé»Ðï)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
rt-PA recombinant tissue-Plasminogen Activator
  = Alteplase
tPA tissue Plasminogen Activator
CAP camptodactyly-arthropathy-pericarditis [syndrome]; Canada Assistance Plan; capsule; captopril; catab...
CGA catabolite gene activator; color graphics adapter
EPA eicosapentaenoic acid; empiric phrase association; Environmental Protection Agency; erect posterior-...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
STAT 2/signal transducer and activator of transcription
Ac Activator
AP Activator Protein
AP-1 Activator Protein 1
AP-2 Activator protein 2
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • k receptor
    k ¼ö¿ë±â
  • kapa receptor
    Ä«ÆÄ ¼ö¿ëü
  • ligand receptor binding
    ¸®°£µå ¼ö¿ë±â °áÇÕ
  • multiple somatic receptor
    ´Ù¹ß¼º ü ¼ö¿ëü, ´Ù¹ß¼º ü ¼ö¿ë±â
  • opiate analgesia receptor
    ¾ÆÆí¼º ÁøÅë ¼ö¿ëü, ¾ÆÆí¼º ÁøÅë ¼ö¿ë±â
  • opiate receptor
    ¾ÆÆí ¼ö¿ëü, ¾ÆÆí ¼ö¿ë±â
    1. ¥ì : ¥ì1Àº µ¿Åë Á¶Àý ¾àÁ¦°¡ °áÇÕ, ¥ì2¿Í °áÇսô ȣÈíÀÌ ¾ïÁ¦µÈ´Ù. 2. ¥ê¿Í °áÇÕ ½Ã Â÷ºÐÇØÁø´Ù. 3. ¥ä : ¸ö¿¡¼­ »ý¼ºµÇ´Â ³»Àμº o
  • peripheral receptor
    ¸»ÃÊ ¼ö¿ëü, ¸»ÃÊ ¼ö¿ë±â
  • pressure receptor
    ¾Ð¼ö¿ë±â, ¾Ð·Â¼ö¿ëü
    µ¿ÀǾî=
  • receptor
    ¼ö¿ë±â, ¼ö¿ëü, °¨¼öü
    1. ¼¼Æ÷Áú ³» ¶Ç´Â ¼¼Æ÷ Ç¥¸é¿¡ Á¸ÀçÇÏ´Â ºÐÀÚ ±¸Á¶·Î¼­
  • receptor activation
    ¼ö¿ëü Ȱ¼ºÈ­, ¼ö¿ë±â Ȱ¼ºÈ­
  • receptor blocking agent
    ¼ö¿ëü Â÷´ÜÁ¦
  • receptor complex
    ¼ö¿ëü º¹ÇÕü, ¼ö¿ë±â º¹ÇÕü
  • receptor destroying enzyme
    ¼ö¿ëü ÆÄ±« È¿¼Ò
    ¼ö¿ëü¸¦ ÆÄ±«ÇÏ¿© ÀûÇ÷±¸ÀÇ ¹ÙÀÌ·¯½º ¿ëÇ÷¿¡ ´ëÇÑ °¨¼ö¼ºÀ» ÀÒ¾î¹ö¸®°Ô ÇÏ´Â È¿¼Ò.
  • receptor potential
    ¼ö¿ë±â ÀüÀ§
    ÀÏÁ¤ÇÑ ¹°¸®È­ÇÐÀû Àڱؿ¡ ´ëÇÏ¿© ½Å°æ ´ÜÀ§ ¼ö¿ëü¿¡¼­ ¹ß»ýÇÏ´Â Å»ºÐ±Ø.
  • receptor site
    ¼ö¿ëü ºÎÀ§, ¼ö¿ëºÎ
    ƯÁ¤ÇÑ »ý¹°ÇÐÀû ¹ÝÀÀÀ» ÃÊ·¡ÇÏ´Â ºÐÀÚ °áÇÕÀÌ ÀϾ´Â ƯÁ¤ ºÎÀ§.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
nuclear inclusion bodies See: inclusion bodies.
(05 Mar 2000)
nuclear jaundice <paediatrics> Disorder due to jaundice in a newborn baby with high blood levels of the pigment bilirubin that is deposited in the brain resulting in damage. The level of bilirubin is monitored in newborns to determine whether treatment is needed to prevent kernicterus. With brain affected, it is also called bilirubin encephalopathy.
(12 Dec 1998)
nuclear lamina <cell biology> A fibrous protein network lining the inner surface of the nuclear envelope. The extent to which this system also provides a scaffold within the nucleus is controversial. Proteins of the lamina are lamins A, B and C, which have sequence homology to proteins of intermediate filaments.
(18 Nov 1997)
nuclear layers of retina The outer nuclear layer, layer 4, of the retina, neuroepithelial layer of retina, and the inner layer, layer 6, of the retina, ganglionic layer of retina.
Synonym: granular layers of retina, stratum nucleare externum et internum retinae.
(05 Mar 2000)
nuclear localization signal Short, predominantly basic amino acid sequences identified as nuclear import signals for some proteins. These sequences are believed to interact with specific receptors at nuclear pores.
(12 Dec 1998)
nuclear magnetic resonance Spectroscopic method of measuring the magnetic moment of atomic nuclei in a covalent bond. Clinical application is in biochemical, metabolic, and physiologic studies of living tissue. It includes proton and electron spin-echo and spin-relaxation times.
(12 Dec 1998)
nuclear magnetic resonance, biomolecular Nmr spectroscopy on small- to medium-size biological macromolecules. This is often used for structural investigation of proteins and nucleic acids, and often involves more than one isotope.
(12 Dec 1998)
nuclear magnetic resonance imaging A special imaging technique used to image internal stuctures of the body, particularly the soft tissues. An MRI image is often superior to a normal X-ray image.
It uses the influence of a large magnet to polarize hydrogen atoms in the tissues and then monitors the summation of the spinning energies within living cells.
Images are very clear and are particularly good for soft tissue, brain and spinal cord, joints and abdomen. These scans may be used for detecting some cancers or for following their progress.
Acronym: MRI
(11 Nov 1997)
nuclear magnetic resonance tomography A special imaging technique used to image internal stuctures of the body, particularly the soft tissues. An MRI image is often superior to a normal X-ray image.
It uses the influence of a large magnet to polarize hydrogen atoms in the tissues and then monitors the summation of the spinning energies within living cells.
Images are very clear and are particularly good for soft tissue, brain and spinal cord, joints and abdomen. These scans may be used for detecting some cancers or for following their progress.
Acronym: MRI
(11 Nov 1997)
nuclear magneton A constant in the equation relating the difference in energies between parallel and antiparallel spin alignments of atomic nuclei in a magnetic field; used in nuclear magnetic resonance spectrometry.
(05 Mar 2000)
nuclear matrix <cell biology> Membrane system that surrounds the nucleus of eukaryotic cells. Consists of inner and outer membranes separated by perinuclear space and perforated by nuclear pores. The term should be used in preference to the term nuclear membrane which is potentially very confusing.
(18 Nov 1997)
nuclear medicine <study> The branch of medicine pertaining to diagnostic, therapeutic and investigative use of radioactive chemical elements.
(16 Dec 1997)
nuclear medicine department, hospital Hospital department responsible for the administration and management of nuclear medicine services.
(12 Dec 1998)
nuclear medicine physician <specialist> A specialist trained in the interpretation and administration of diagnostic tests that use radionuclide compounds.
(27 Sep 1997)
nuclear membrane An intracellular structure, consisting of two concentric membranes, enclosing the nucleoplasm and separating it from the cytoplasm. The areas where these two membranes fuse are called nuclear pore complexes.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á